Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 11—November 2015
Research

Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010–2013

Kimiko UbukataComments to Author , Naoko Chiba, Shigeo Hanada, Miyuki Morozumi, Takeaki Wajima, Michi Shouji, Satoshi Iwata, and Invasive Pneumococcal Diseases Surveillance Study Group
Author affiliations: Keio University School of Medicine, Tokyo, Japan (K. Ubukata, N. Chiba, M. Morozumi, S. Iwata); Toranomon Hospital, Tokyo (S. Hanada); Tokyo University of Pharmacy and Life Sciences, Tokyo (T. Wajima); National Cancer Center Hospital, Tokyo (M. Shouji)

Main Article

Table 2

Isolates positive for invasive pneumococcal diseases and resistant to penicillin, macrolide, and quinolone, by genotype, Japan, April 2010–March 2013*

Genotype Total, no. (%), N = 715 2010–2011, no. (%), n = 275 2011–2012, no. (%), n = 213 2012–2013, no. (%), n = 227 p value†
Penicillin resistance
gPSSP 115 (16.1) 42 (15.3) 40 (18.8) 33 (14.5) 0.431
gPISP (pbp2x) 286 (40.0) 96 (34.9) 89 (41.8) 101 (44.5) 0.076
gPISP (pbp2b) 9 (1.3) 5 (1.8) 0 4 (1.8) ND
gPISP (pbp1a+2x) 73 (10.2) 30 (10.9) 23 (10.8) 20 (8.8) 0.701
gPISP (pbp1a+2b) 4 (0.6) 3 (1.1) 1 (0.5) 0 ND
gPISP (pbp2x+2b) 42 (5.9) 10 (3.6) 11 (5.2) 21 (9.3) 0.025
gPRSP (pbp1a+2x+2b)
186 (26.0)
89 (32.4)
49 (23.0)
48 (21.1)
0.008
Macrolide resistance
Resistance gene (-) 74 (10.3) 34 (12.4) 16 (7.5) 24 (10.6) 0.216
mef(A) gene 169 (23.6) 63 (22.9) 56 (26.3) 50 (22.0) 0.538
erm(B) gene 407 (56.9) 152 (55.3) 123 (57.7) 132 (58.1) 0.777
mef(A) and erm(B)
65 (9.1)
26 (9.5)
18 (8.5)
21 (9.3)
0.925
Quinolone resistance‡
gyrA+parC 5 (0.7) 2 (0.7) 3 (1.4) 0 ND
parC 9 (1.3) 5 (1.8) 1 (0.5) 3 (1.3) ND

*Years run from April 1–March 31 of the following year. ND, not determined because of a low number of strains.
†p values characterize comparison of the 3 surveillance periods.
‡Quinolone resistance, Ser81Phe substitution in GyrA and Ser79Tyr in ParC, respectively.

Main Article

Page created: October 16, 2015
Page updated: October 16, 2015
Page reviewed: October 16, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external